Searched for: in-biosketch:true
person:kaufmh06
ELP1 Gene Variants in Familial Dysautonomia
Kaufmann, Horacio; Gonzalez Duarte, Alejandra; Dalamo, Kaia; Barnett, Andreana; Millar Vernetti, Patricio; Axelrod, Felicia; Lowther, Chelsea; Pigini, Paolo; Harripaul, Ricardo S; Gao, Dadi; Morini, Elisabetta; Slaugenhaupt, Susan A
BACKGROUND AND OBJECTIVES/UNASSIGNED:c.2204 + 6C > T. METHODS/UNASSIGNED:Patients referred to the NYU Dysautonomia Center with suspected FD underwent comprehensive evaluations, including clinical assessments, neurologic examinations, and genetic testing. RESULTS/UNASSIGNED:c.725C > T. All patients exhibited the full spectrum of FD manifestations. Their self-reported ancestry was diverse: 1 patient was born in Canada to AJ parents, 1 was born in Poland, and 2 were born in the United States, including 1 with African American ancestry; 3 were unaware of any AJ heritage despite carrying the major AJ allele. DISCUSSION/UNASSIGNED:variants during genetic testing when FD is clinically suspected.
PMCID:13759262
PMID: 43031572
ISSN: 2376-7839
CID: 6075947
ELP1 Gene Variants in Familial Dysautonomia
Kaufmann, Horacio; Gonzalez Duarte, Alejandra; Dalamo, Kaia; Barnett, Andreana; Millar Vernetti, Patricio; Axelrod, Felicia; Lowther, Chelsea; Pigini, Paolo; Harripaul, Ricardo S; Gao, Dadi; Morini, Elisabetta; Slaugenhaupt, Susan A
BACKGROUND AND OBJECTIVES/UNASSIGNED:c.2204 + 6C > T. METHODS/UNASSIGNED:Patients referred to the NYU Dysautonomia Center with suspected FD underwent comprehensive evaluations, including clinical assessments, neurologic examinations, and genetic testing. RESULTS/UNASSIGNED:c.725C > T. All patients exhibited the full spectrum of FD manifestations. Their self-reported ancestry was diverse: 1 patient was born in Canada to AJ parents, 1 was born in Poland, and 2 were born in the United States, including 1 with African American ancestry; 3 were unaware of any AJ heritage despite carrying the major AJ allele. DISCUSSION/UNASSIGNED:variants during genetic testing when FD is clinically suspected.
PMCID:13759262
PMID: 43031572
ISSN: 2376-7839
CID: 6075948
Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial
Freeman, Roy; Kaufmann, Horacio; Biaggioni, Italo; Iodice, Valeria; Jordan, Jens; Vickery, Ross; Geurin, Tadhg; Kmiecik, Matthew J; Norcliffe-Kaufmann, Lucy
BACKGROUND AND OBJECTIVES/OBJECTIVE:Degeneration of the central autonomic network with relative sparing of peripheral autonomic neurons underlies neurogenic orthostatic hypotension in patients with multiple system atrophy (MSA). Ampreloxetine, a novel, selective, norepinephrine (NE) reuptake inhibitor, allows once-daily dosing to precisely target residual peripheral autonomic neurons. Based on the hypothesis that patients with MSA would be most responsive and the substantial unmet need for symptomatic therapy in this population, an MSA subgroup analysis was prespecified. METHODS:We conducted a run-in 4-week, parallel-group, randomized controlled trial (SEQUOIA), followed by a pivotal enriched randomized withdrawal (RW) trial with 16-week open-label treatment and 6 weeks of 1:1 RW (REDWOOD). Inclusion criteria for the MSA subgroup included (1) probable or possible MSA, (2) 3-minute orthostatic blood pressure (BP) fall >20/10 mm Hg, and (3) dizziness or lightheadedness score >4 points. Outcome measures included self-reported symptom burden captured on the 10-item OH Questionnaire (OHQ). Differences were analyzed using logistic regression and mixed-model repeated measures analysis. RESULTS:= 0.015). Standing BP remained unchanged from open-label in the ampreloxetine group (systolic: 5.6 ± 4.1; diastolic: 3.7 ± 2.9 [SE] mm Hg) but fell after placebo withdrawal (systolic: -10.0 ± 4.5; diastolic: -6.0 ± 3.1 mm Hg). The catecholamine profile was consistent with NE transporter inhibition. There were no observed increases in supine BP. DISCUSSION/CONCLUSIONS:In a prespecified subgroup analysis of MSA participants in the REDWOOD trial, patients randomized to placebo worsened, whereas those who were randomized to treatment maintained their open-label level of function. TRIAL REGISTRATION INFORMATION/UNASSIGNED:REDWOOD trial, NCT03829657; first submitted to registry January 10, 2019; first participant enrolled February 22, 2019. SEQUOIA trial, NCT03750552; first submitted to registry November 20, 2018; first participant enrolled January 24, 2019. See ClinicalTrials.gov for full-protocol and statistical analysis plan. CLASSIFICATION OF EVIDENCE/METHODS:This study provides Class III evidence that in patients with MSA who had symptomatic benefit on orthostatic hypotension with ampreloxetine, there was no difference in the odds of treatment failures between those maintained on ampreloxetine and those withdrawn to placebo.
PMID: 42475649
ISSN: 1526-632x
CID: 6070523
Autonomic Dysfunction in Long COVID Is Distinct From Pure Autonomic Failure
Vernino, Steven; Bryarly, Meredith; Robbins, Nathaniel M; Freeman, Roy; Gibbons, Christopher; Shibao, Cyndya A; Biaggioni, Italo; Kaufmann, Horacio; Levine, Benjamin D
PMID: 42454777
ISSN: 1558-3597
CID: 6066822
Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure
Millar Vernetti, Patricio; Palma, Jose-Alberto; Biaggioni, Italo; Shibao, Cyndya A; Freeman, Roy; Gibbons, Christopher; Singer, Wolfgang; Coon, Elizabeth A; Miglis, Mitchell G; Krismer, Florian; Fanciulli, Alessandra; Goldstein, David S; Betensky, Rebecca A; Kaufmann, Horacio
BACKGROUND:The Movement Disorder Society (MDS) research criteria for possible prodromal multiple system atrophy (PP-MSA) have not been prospectively validated. OBJECTIVE:To evaluate the diagnostic performance of the PP-MSA criteria in a longitudinal cohort of patients with pure autonomic failure (PAF) and to assess whether additional clinical features improve their predictive value. METHODS:Seventy-six patients with PAF enrolled across eight centers in the Natural History Study of the Synucleinopathies were followed for ≥6 years or until phenoconversion. Participants were classified according to MDS PP-MSA criteria and followed for development of MSA, Parkinson's disease, or dementia with Lewy bodies. Diagnostic performance was assessed longitudinally. Analyses were repeated using a stricter olfactory threshold (University of Pennsylvania Smell Identification Test [UPSIT]≤28) as an exclusion criterion. RESULTS:Thirty-eight participants met PP-MSA criteria, of whom 12 phenoconverted to MSA within 6 years. Sensitivity was 100% at year 1 and 92% at year 6, whereas specificity ranged from 56% to 67%. Positive predictive value (PPV) ranged from 21% to 34%. Applying a stricter olfactory threshold improved specificity (90%-97%) and PPV (53%-83%), with a modest reduction in sensitivity (to 83%). Participants who phenoconverted to MSA were younger, had more severe urinary dysfunction, and greater orthostatic heart rate responses. CONCLUSIONS:The PP-MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF. A stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials. © 2026 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
PMID: 42444112
ISSN: 1531-8257
CID: 6066492
Addressing the needs of nano-rare patients: the n-Lorem experience
Crooke, Stanley T; Glass, Sarah; Gleeson, Joseph G; Mignon, Laurence; Skourti-Stathaki, Konstantina; Douville, Julie; Knutsen, Megan; Pu, He; Bain, Jennifer M; Berry-Kravis, Elizabeth; Shneider, Neil A; Kim-McManus, Olivia; Eichler, Florian S; Chung, Wendy K; Nagy, Amanda; Kaufmann, Horacio; Gonzalez-Duarte, Alejandra; Oskarsson, Björn; McCourt, Emily A; Leung, Nelson
Patients with extremely rare pathogenic variants pose unique challenges to current healthcare systems. Nano-rare mutations have been defined as mutations with a known prevalence of <30 patients worldwide, but because of the small fraction of humans who have undergone genetic testing, neither the precise prevalence of individual mutations nor the total prevalence of patients with nano-rare mutations is known. n-Lorem is a non-profit founded in 2020 with the mission of equitably discovering, developing, and providing bespoke experimental antisense oligonucleotides (ASOs) for free, for life, to patients with nano-rare mutations that are amenable to ASO treatment. In this perspective, we provide an overview of the n-Lorem processes and systems, the characteristics of the first 329 patients who have applied for treatment for whom initial assessment was completed and suitability for ASO treatment determined, and a summary of the results of ASO treatment for patients treated to date. Detailed data on individual patients and the overall clinical safety and tolerability profiles of the ASOs for which there are clinical data are the subjects of other manuscripts.
PMCID:13227102
PMID: 42227334
ISSN: 1362-4962
CID: 6043682
Long-term outcomes of hyperadrenergic orthostatic hypotension [Letter]
Castro, Robert A; Mehr, Pouya E; Vernetti, Patricio Millar; Mwesigwa, Naome; Biaggioni, Italo; Raj, Satish R; Shehata, Esraa; Hackstadt, Amber J; Ding, Tan; Kaufmann, Horacio; Shibao, Cyndya A
PMID: 42141334
ISSN: 1619-1560
CID: 6037262
Clinical autonomic research: welcome to 2026 [Editorial]
Macefield, Vaughan G; Kaufmann, Horacio; Jordan, Jens
PMID: 41741922
ISSN: 1619-1560
CID: 6010232
Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan
Kaufmann, Horacio; Palma, Jose-Alberto; Millar Vernetti, Patricio; Kuijpers, Mechteld; Nkrumah, Grace; Kang, Un Jung; Ma, Thong; Betensky, Rebecca A; Claassen, Daniel O; Vemuri, Prashanthi; Trujillo, Paula; Siderowf, Andrew; Soto, Claudio; Feigin, Andrew S; Stebbins, Glenn T; Lindahl, Joe; Qureshi, Irfan; Berger, Anna-Karin; Husnik, Marla; Fanciulli, Alessandra; Poewe, Werner; Krismer, Florian; Biaggioni, Italo; Singer, Wolfgang; ,
PURPOSE/OBJECTIVE:The Unified Multiple System Atrophy Rating Scale (UMSARS) is widely used as an outcome measure in MSA trials, but it has limitations for clinical trial use. To address these, we developed the Multiple System Atrophy Combined Outcome Assessment (MuSyCA), a comprehensive multimodal tool for disease-modifying MSA trials. The purpose of this manuscript is to describe the development and validation plan for MuSyCA, with emphasis on its structure, intended use, and assessment of reliability, validity, and sensitivity in tracking disease progression. METHODS:The development of MuSyCA followed a multistep process. Candidate outcome assessments were identified through systematic literature review and analysis of longitudinal data from large MSA cohorts. Content was refined through multiple Delphi-like consensus rounds involving MSA experts, patient advocacy groups representatives, and industry stakeholders. Cognitive interviews conducted in 20 patients with MSA evaluated the clarity and clinical relevance of patient- and clinician-reported outcomes; feedback was incorporated into a subsequent version of the MuSyCA. Validation is ongoing and includes assessment of construct validity, internal consistency, test-retest reliability, and responsiveness. Longitudinal analyses to determine sensitivity to change over time are ongoing. RESULTS:MuSyCA combines patient- and clinician-reported outcomes, biomarkers (neurofilament light chain, neuroimaging), and performance-based measures to capture subjective and objective aspects of MSA progression, enhancing its utility to detect treatment effects in clinical trials. MuSyCa is not intended to be used in clinical practice. CONCLUSIONS:MuSyCA offers a multidimensional approach to MSA assessment, supporting precise, disease-relevant evaluations in trials of putative disease-modifying therapies. Its validation will provide a standardized multimodal outcome measure, advancing MSA therapeutic development.
PMID: 41762390
ISSN: 1619-1560
CID: 6010702
Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia
Gibbons, Christopher H; Levine, Todd; Adler, Charles H; Bellaire, Bailey; Wang, Ningshan; Agarwal, Pinky; Aldridge, Georgina M; Barboi, Alexandru; Claassen, Daniel; Evidente, Virgilio G H; Galasko, Douglas; Gonzalez-Duarte, Alejandra; Gil, Ramon; Gudesblatt, Mark; Isaacson, Stuart H; Kaufmann, Horacio; Khemani, Pravin; Kumar, Rajeev; Lamotte, Guillaume; Liu, Andy J; McFarland, Nikolaus R; Miglis, Mitchell G; Reynolds, Adam; Sahagian, Gregory A; Saint-Hilaire, Marie-Helene; Schwartzbard, Julie B; Singer, Wolfgang; Soileau, Michael J; Vernino, Steven; Millar Vernetti, Patricio; Yerstein, Oleg; Freeman, Roy
OBJECTIVE:To determine the test performance of cutaneous phosphorylated alpha-synuclein (P-SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. METHODS:This is the first subgroup analysis of the Synuclein-One study, a prospective, blinded study evaluating P-SYN detection from skin biopsies in 218 subjects with a referral diagnosis of control (N = 151) and DLB (N = 67). All subjects completed detailed examinations, questionnaires, and had skin biopsies for detection of P-SYN. DLB patients were included if meeting the 4th DLB consensus probable criteria. Control subjects, aged 40-99, had no history, examination findings, or symptoms suggestive of a synucleinopathy or neurodegenerative disease. An expert review panel, blinded to pathological data, determined the final diagnosis. Controls with reduced MoCA (MoCA < 26, N = 26) at screening were analyzed separately. RESULTS:After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. The proportions of subjects with cutaneous P-SYN detected by skin biopsy were 96.0% (48 of 50) of the DLB group, 31% (8 of 26) of the controls with reduced MoCA, and 3.3% (4 of 120) of the controls with normal MoCA. INTERPRETATION/CONCLUSIONS:In this prospective, blinded, cross-sectional study, a high proportion of subjects meeting clinical consensus criteria for DLB had P-SYN detected in skin biopsies. Almost 1/3 of subjects with reduced MoCA testing also had P-SYN detected. These results support a role for skin biopsy detection of P-SYN in patients with DLB. TRIAL REGISTRATION/BACKGROUND:NCT04700722.
PMID: 41449577
ISSN: 2328-9503
CID: 6005862